TICKERNERD
Menu
BHVNBHVNHealthcare · Biotechnology

BHVN Stock Forecast: Biohaven Ltd. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$13
−0.63% on the day

The 16 Wall Street analysts covering Biohaven Ltd. hold a median 12-month price target of $20 — +57.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.9B
Ticker Nerd rank
30 / 100
Median analyst target
$20
Analysts covering
16
Revenue$0.0
Operating income−$124.9M
Net income−$137.3M
Free cash flow−$85.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−19.9%
1M
−12.3%
YTD
+12.6%
1Y
−9.7%
From 52W high
−29.8%
From 52W low
+63.2%
$8
$18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BHVN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Biohaven Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
30 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
79
Accruals
73
Revisions
47
Value
46
Size
37
Volatility
34
Momentum
34
Quality
17
Issuance
16

Growth (79): Sales and profits are climbing, and climbing faster than before.

Issuance (16): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BHVN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BHVN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40Oct 25Jan 26Apr 26Jul 26BHVNHigh $42Median $20Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says16 analysts
12 Buy3 Hold1 Sell
Low $10Median $20High $42

The green dot is the last close — the median target sits +57.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
10 Sept 2026HC Wainwright & Co.ReiteratesNeutral$10
8 Sept 2026RBC CapitalDowngradeSector Perform$23 → $19
12 Aug 2026Morgan StanleyMaintainsOverweight$18 → $19
12 Aug 2026Morgan StanleyMaintainsOverweight—
11 Aug 2026RBC CapitalMaintainsOutperform$22 → $23
11 Aug 2026RBC CapitalMaintainsOutperform—
29 June 2026B of A SecuritiesDowngradeUnderperform$12 → $11
29 June 2026B of A SecuritiesDowngradeUnderperform—
26 May 2026HC Wainwright & Co.ReiteratesNeutral—
13 May 2026Morgan StanleyMaintainsOverweight—
5 May 2026RBC CapitalMaintainsOutperform—
2 Apr 2026CitigroupMaintainsBuy—
11 Mar 2026TD CowenMaintainsBuy—
4 Mar 2026HC Wainwright & Co.MaintainsNeutral—
3 Mar 2026RBC CapitalMaintainsOutperform—
21 Jan 2026RBC CapitalUpgradeOutperform—
6 Jan 2026Morgan StanleyMaintainsOverweight—
26 Dec 2025HC Wainwright & Co.ReiteratesNeutral—
3 Dec 2025HC Wainwright & Co.DowngradeNeutral—
26 Nov 2025UBSDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BHVN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BHVN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Biohaven Ltd. returned −9.7% against +17.5% for the S&P 500, dividends included.

BHVN vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120Oct 25Jan 26Apr 26Jul 26BHVNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BHVN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Biohaven Ltd. (BHVN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.9×

Cheaper than 85% of US stocks

Price / sales
—
Price / book
156.9×

Cheaper than 1% of US stocks

EV / EBITDA
−3.7×

Cheaper than 77% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−799.5%

Higher than 2% of US stocks

Return on assets
−72.0%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Biohaven Ltd. (BHVN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Biohaven Ltd. has a market value of $1.9B and an enterprise value of $1.9B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$586.8M.

  • Diluted earnings per share, trailing twelve months: $−4.64.

  • Free cash flow in the twelve months to 30 June 2026: −$511.9M.

  • Shares outstanding: 151.0M.

  • Trailing P/E: −1.9×; forward P/E: −6.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Biohaven Ltd. employs 274 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

BHVN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BHVNBiohaven Ltd.$1.9B
30
COAGHemab Therapeutics Holdings, Inc.$1.8B
1
GHRSGH Research PLC$1.9B
66
ZYMEZymeworks, Inc.$1.9B
77
STOKStoke Therapeutics, Inc.$1.8B
53
VIRVir Biotechnology, Inc.$1.8B
94
VCELVericel Corp.$1.9B
94

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Biohaven Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BHVN news & analysis

Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)

PRNewsWire · 11 Sept 2026negative

A law firm has notified investors of a pending investigation into Biohaven after the company's shares fell about 14.73% on September 10, 2026. The decline followed Biohaven's disclosure that the FDA placed a partial clinical hold on new-patient enrollment in its BHV-7000/opakalim epilepsy trials.

Why it matters — The FDA partial clinical hold on new-patient enrollment in a key epilepsy program and the resulting investigation could affect the outlook for one of Biohaven's major pipeline assets.

Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.

Barrons · 10 Sept 2026negative

Regulators placed a partial hold on a clinical study for Biohaven's epilepsy drug candidate, opakalim. The news comes as Biohaven's stock is already declining, and a rival drugmaker stands to benefit from the setback.

Why it matters — A partial clinical hold on a key pipeline candidate like opakalim represents another setback for Biohaven and could affect the company's development timeline and competitive position.

FDA Pauses New Enrollment for Biohaven Epilepsy Drug Program

Benzinga · 10 Sept 2026negative

Biohaven Ltd. announced that the U.S. Food and Drug Administration issued a partial clinical hold on new patient enrollment for its BHV-7000 epilepsy drug program. The company stated that timelines for its lead pivotal study in refractory focal epilepsy remain intact.

Why it matters — An FDA partial clinical hold on a key pipeline program is a significant regulatory development for Biohaven and could affect the company's epilepsy development outlook.

Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback

Investors Business Daily · 10 Sept 2026negative

Biohaven stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment due to safety concerns. The move was noted as a boon for rival Xenon.

Why it matters — A BHVN watcher would care because the company paused enrollment in a midstage seizure-treatment study over safety concerns, casting doubt on that program's development.

US FDA pauses new enrollment in Biohaven's epilepsy drug trials

Reuters · 10 Sept 2026negative

The U.S. FDA imposed a partial clinical hold on Biohaven's experimental epilepsy drug, pausing new patient enrollment in its trials after rodent findings were observed. The announcement on Thursday sent Biohaven's shares down more than 13% in premarket trading.

Why it matters — A partial clinical hold on a key experimental drug in its pipeline is a significant regulatory setback for Biohaven that could delay development of the epilepsy program.

FAQ

Frequently asked questions about BHVN stock

What is the BHVN stock price forecast for 2026-2027?

The 16 Wall Street analysts covering Biohaven Ltd. have a median 12-month price target of $20, with estimates ranging from $10 to $42. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BHVN stock a buy right now?

Of the 16 analysts covering Biohaven Ltd., 12 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Biohaven Ltd. 30 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BHVN?

As at 12 Sept 2026, Biohaven Ltd. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (79 of 100).

Will BHVN stock go up?

No one can know that. What the data says: the median 12-month target from 16 analysts implies +57.4% from the last close, and Ticker Nerd's factor model ranks Biohaven Ltd. 30 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BHVN stock forecast for 2030?

No analyst covering Biohaven Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BHVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $42 over the next 12 months.

How has BHVN stock performed over the past year?

Biohaven Ltd. returned -9.7% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Biohaven Ltd. do?

Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies in immunology, obesity, neuroscience, and oncology.

What is the latest news on BHVN?

The most recent item we track (PRNewsWire, 11 Sept 2026): "Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)". A law firm has notified investors of a pending investigation into Biohaven after the company's shares fell about 14.73% on September 10, 2026. The decline followed Biohaven's disclosure that the FDA placed a partial clinical hold on new-patient enrollment in its BHV-7000/opakalim epilepsy trials.

Company

About Biohaven Ltd.

Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies in immunology, obesity, neuroscience, and oncology. The company’s current portfolio includes drug candidates for neurological and neuropsychiatric disorders, epilepsy, pain, neuroinflammatory conditions, and rare diseases, alongside programs aimed at immune-mediated and cancer-related indications. Biohaven uses multiple proprietary development platforms, including approaches such as ion channel modulation, extracellular protein degradation, and antibody-drug conjugates, to build a diversified pipeline of investigational medicines. Headquartered in New Haven, Connecticut, Biohaven serves as a research-driven biopharmaceutical platform centered on advancing novel treatments across both common and underserved disease areas.

CEO Dr. Vladimir Coric M.D. · 274 employees · United States · https://www.biohaven.com